All News Items
Healthy kidneys despite hypertension
31.05.2023 / A mutation that causes severe hypertension also protects the kidneys from being damaged, reports a team led by Enno Klußmann of the Max Delbrück Center and the DZHK in “Kidney International”. The researchers are now exploring how the effects of the mutated gene can be used therapeutically. … more
€4.6 million for a novel CAR T-cell therapy
30.05.2023 / While CAR-T cells have proven successful in treating certain types of leukemia and lymphoma, these immunotherapies can become even more effective. A clinical trial run by Charité and the Max Delbrück Center has been awarded a grant of several million euros to test a new approach. … more
Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA
30.05.2023 / By organizing the first Boston Radionuclide Theranostics Forum and bringing together numerous renowned experts in Boston, Mass., Eckert & Ziegler underscores its leading position in the field of radiopharmaceuticals. On June 1st, 2023, the company will connect potential and existing partners as well as key industry players to dive into a vigorous discussion on the central topics of the rapidly developing radiotheranostics market. The Forum will discuss solutions to challenges in supply chain, upscaling and patient access as well as the latest theranostic concepts. … more
The mechanisms behind swallowing
25.05.2023 / Sensory cells in the vagus nerve can detect and locate food in the esophagus. Their signals help transport the food onward to the stomach. Signal failure leads to swallowing disorders, say a team led by Carmen Birchmeier at the Max Delbrück Center. They have published their findings in “Neuron.” … more
Reorganization in the Executive Board of Eckert & Ziegler
16.05.2023 / The Supervisory Board of Eckert & Ziegler AG has now formally approved the reorganization of the Executive Board already announced in December 2022. Accordingly, the founder and Chairman of the Executive Board, Dr. Andreas Eckert, and the Chief Operating Officer of the Medical segment, Dr. Lutz Helmke, will resign from their positions at the end of the Annual General Meeting on June 7, 2023, by mutual agreement. Their responsibilities and the chairmanship of the Executive Board will be taken over by the current Chief Sales Officer of the Medical segment, Dr. Harald Hasselmann. Newly appointed to the Executive Board and responsible for the Isotope Products segment will be Frank Yeager, the longtime head of this California based business unit. The positions of Dr. Hakim Bouterfa and Jutta Ludwig on the Management Board remain unaffected by the changes. … more
Interview about Berlin-Buch – A Location for Future Innovation
13.05.2023 / The BerlinBioCube incubator is currently being built on Campus Berlin-Buch. The new five-story building provides a total of 8,000 m² of space for state-of-the-art laboratories, offices, and shared spaces. |transkript spoke to the Managing Director. … more
Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023
11.05.2023 / Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 16% to EUR 57.9 million in the first quarter of 2023. Net income amounted to EUR 4.7 million or EUR 0.23 per share and was thus 29% lower than in the same quarter of the previous year, mainly due to currency losses as well as inflation adjustments. … more
How cancer genes become independent
05.05.2023 / Sometimes a tumor suddenly starts growing rapidly or becomes resistant to cancerdrugs. This can be caused by a cancer gene “striking out on its own” in ring shapes. ECRC-scientist Anton Henssen described how these DNA rings arise and continue to develop in the journal “Nature Genetics”. … more
Berlin-Buch goes BIO International Convention
05.05.2023 / The BIO International Convention attracts 14,000+ biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships. One of the companies attending is Campus Berlin-Buch GmbH. … more
Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
20.04.2023 / Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), has received the manufacturing authorization for Lutetium-177 (non-carrier-added Lu-177) in GMP grade from the competent German authority. The approval is the basis for the marketing authorization of Lutetium-177 as a drug, but also for use of this radioisotope as a starting material for the manufacture of radiopharmaceuticals. By making Lutetium available to a significantly broader range of users, the approval will enable Eckert & Ziegler to further continue its successful strategy as one of the world leading isotope suppliers. … more
Ariceum Therapeutics Announces Extension of Series A Financing to EUR 47.75M to Advance its Next Generation Radiopharmaceutical Clinical Pipeline
19.04.2023 / Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces the successful completion of a Series A extension financing, raising a further EUR 22.75 million, following the EUR 25 million Series A financing announced in June 2022. The financing was co-led by new investors Andera Partners and Earlybird Venture Capital, with participation from existing investor Pureos Bioventures, now doubling its original investment in the Company. As part of the investment, Olivier Litzka, Partner at Andera Partners, and Christoph Massner, Principal at Earlybird, will join the Ariceum Board of Directors. … more
CELLphenomics’ and KYAN Therapeutics combined platforms provide best-in-class solutions to support the biopharma industry
14.04.2023 / CELLphenomics and KYAN Therapeutics announced their new partnership today. By combining KYAN's technology platform, Optim.AI™ - which utilizes artificial intelligence to predict the effects of drug combinations and CELLphenomics' proprietary PD3D® technology, this partnership aims to offer an efficient approach to expedite drug development process in the biopharmaceutical industry. The combination of these two unique technologies will allow reliable conclusions about the treatability of the tumor and its functional causes of therapeutic success and/or failure, leading to novel treatment combinations and faster preclinical development of new anti-cancer drugs. … more
How skates learned to fly through water
13.04.2023 / Genes are not the only drivers of evolution. The iconic fins of skates are caused by changes in the non-coding parts of the genome and its three-dimensional structure, a research team including Darío Lupiáñez at the Max Delbrück Center reports in “Nature”. … more
Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
12.04.2023 / Eckert & Ziegler’s fully owned subsidiary Qi Kang Medical Technology Ltd. (QKM) has recently received the authorization for its Environmental Impact Assessment (EIA) from the Department of Ecology and Environment of Jiangsu Province in China. The responsible authorities approved QKM’s planned construction of a radioisotope production facility consisting of clean rooms for sealed and non-sealed radioactive material, laboratories for quality control and microbiology. The ratified EIA also includes the installation of a cyclotron with a maximum proton energy of 30MeV. … more
Autoantibodies in COVID-19: not always harmful?
04.04.2023 / Critically ill COVID-19 patients often have antibodies in their blood that bind to the body’s own structures. But these autoantibodies frequently bind to multiple targets, Kathrin de la Rosa’s team reports in “European Journal of Immunology.” This calls into question their role in disease progression. … more
Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
04.04.2023 / Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225 (non-carrier-added Ac-225). Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT’s pipeline of next generation Ac-225-based radioligands. … more
Nasal vaccine to prevent COVID-19 passes first tests
04.04.2023 / Since the beginning of the COVID-19 pandemic, researchers have been working on mucosal vaccines that can be administered through the nose. Now, scientists in Berlin have developed a live attenuated vaccine for the nose. In “Nature Microbiology”, they describe the special immune protection it induces. … more
Long awaited by the pharma industry
28.03.2023 / It takes great patience and perseverance to turn research findings into new technologies or therapies. The Helmholtz Initiative and Networking Fund gives financial support to “pathfinder projects” that are particularly promising. Researchers at the Max Delbrück Center have now won grants for three projects. … more
Eckert & Ziegler Plans Change of Legal Form to European Stock Corporation (SE)
25.03.2023 / The Executive Board and Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) have decided to prepare the conversion of the company into a European Company (Societas Europaea, SE) by changing its legal form. The dualistic management system, consisting of an Executive Board as the management body and a Supervisory Board as the supervisory body, is also to continue under the SE legal form. Responsibilities and composition of the executive board and supervisory board remain unaffected by the new structure. The registered office of the company shall continue to be in Berlin. … more
Eckert & Ziegler with Unchanged Dividend Proposal
24.03.2023 / … more
Novel disease models for multiple myeloma
16.03.2023 / A team of scientists led by Martin Janz and Klaus Rajewsky at the Max Delbrück Center has successfully generated genetically defined mouse models for two subtypes of multiple myeloma. These models will contribute to a better understanding of how the disease develops in humans. The team has now published their findings in the journal PNAS. … more
Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.
03.03.2023 / Eckert & Ziegler (ISIN DE0005659700, SDAX) has successfully submitted a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration for lutetium (177Lu) chloride solution (containing no-carrier-added radioisotope Lutetium-177), an active pharmaceutical ingredient and received DMF registration number 038043. … more
The harmful effects of immune cells in hypertension
23.02.2023 / Hypertension can damage the heart, brain, and blood vessels. The immune system plays an important role in this process, Suphansa Sawamiphak from the Max Delbrück Center reports in Cardiovascular Research. The study, using zebrafish, found that inflammation causes macrophages to damage blood vessels instead of protecting them. … more
Evolution: Miniproteins appeared “from nowhere”
17.02.2023 / Evolutionarily young miniproteins are unique in humans, and researchers have recently discovered thousands of them. Writing in Molecular Cell, Norbert Hübner and colleagues from the BIH and other institutions describe the origins of these tiny proteins and explain that they probably influence important cellular processes. … more
Jury selects the best in youth science contest
17.02.2023 / “Mach Ideen groß” is the theme of this year’s nationwide “Jugend forscht” competition. At Campus Berlin-Buch the young scientists presented more than 20 projects. Seven of them made it to the regional championship. … more
How the brain encodes warm and cool
13.02.2023 / Researchers from the Max Delbrück Center have found a region of the brain that is responsible for our perception of temperature when we touch things. The paper, which appears in “Nature”, reports the discovery of a ‘thermal cortex’ located in a posterior region of the insular cortex. … more
State Secretary Naghipour visits Campus Berlin-Buch
10.02.2023 / Armaghan Naghipour, State Secretary for Science, Research and Equality, informed herself about the development of the Berlin-Buch Science and Biotech Campus on February 10, 2023. … more
Salt cuts off the energy supply to immune regulators
09.02.2023 / Regulatory T cells ensure that immune responses happen in a controlled way. But eating too much salt weakens these cells’ energy supply, thus rendering them dysfunctional for a while. This may have implications for autoimmunity, an international team – including Dominik Müller – reports in “Cell Metabolism.” … more
How the body’s defenses keep their weapons in check
03.02.2023 / The signaling molecules of the immune system should trigger a response only where necessary. To prevent a life-threatening spread to the rest of the body, connective tissue can absorb these molecules like a sponge. A team led by Thomas Blankenstein presents this mechanism in “Nature Immunology. … more
Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting
01.02.2023 / The Lausanne University Hospital (CHUV) has reported the initial dosing of a patient in a phase II clinical study investigating the sensitivity of PENTIXAFOR (Boclatixafotide) in a cardiovascular and inflammatory setting. It is the first time that Eckert & Ziegler’s proprietary CXCR4-compound is used in an advanced clinical test in a non-cancer indication, opening the way for a broader use of PENTIXAFOR outside of oncology. … more
ERC Proof of Concept Grant for Mina Gouti
24.01.2023 / Organoids have to be fed and cared for continuously so that they can mature. So far, it is mostly a manual process – not suitable for industrial drug screening. Now, the European Research Council (ERC) has awarded Mina Gouti a Proof of Concept Grant to tackle scalability and reproducibility. … more
Paul Ehrlich foundation honors Leif S. Ludwig
24.01.2023 / Leif S. Ludwig, a researcher at the Max Delbrück Center and the Berlin Institute of Health at Charité (BIH), will receive the Paul Ehrlich and Ludwig Darmstaedter Young Investigator Award 2023 for a new method to analyze the formation of blood cells, as the Scientific Council of the Paul Ehrlich Foundation announced today. … more
Inborn immunodeficiency discovered – and explained
23.01.2023 / A group of international researchers – among them Stephan Mathas from the ECRC – has found that changing a single segment of the genome causes a previously unknown immunodeficiency in humans. The paper, which appears in Science Immunology, reports the discovery of a point mutation in the transcription factor IRF4. … more
Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures
17.01.2023 / Insider information pursuant to Article 17 MAR … more
Deep expertise, and a bold vision: MyoPax launches in Berlin
04.01.2023 / MyoPax develops regenerative therapies for previously incurable muscle diseases. An interview with co-founders Prof. Simone Spuler and Dr. Verena Schöwel-Wolf, now board member and CEO respectively … more
Change in the Supervisory Board of Eckert & Ziegler AG
20.12.2022 / Eckert Wagniskapital und Frühphasenfinanzierung GmbH has appointed radiation physicist Paola Eckert-Palvarini as its new representative on the Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, SDAX). … more
Changes in the Management Board of Eckert & Ziegler
19.12.2022 / The founder and CEO of Eckert & Ziegler AG (ISIN DE0005659700, SDAX), Dr. Andreas Eckert, today gave notice to the company that he intends to transfer from the Management to the Supervisory Board after the company’s General Shareholder Meeting in mid-2023. Before that the Supervisory Board appointed, for a period of two years effective 1 January 2023, two additional new Executive Directors, Dr. Hakim Bouterfa as Chief Medical Officer and Jutta Ludwig as Head of Asia. Both are already with the Eckert & Ziegler and shall now, albeit on the Board level, support Dr. Harald Hasselmann, whom Eckert recommended as his successor. … more
Starvation causes cell remodelling
17.12.2022 / Body cells burn off fat reserves when nutrient supply from food ceases. A team led by Professor Volker Haucke and Dr. Wonyul Jang from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) has now discovered a previously unknown mechanism for how this “starvation response” is triggered, and what can inhibit it. The results have been published in the renowned international journal Science. … more
Understanding the transition to disease
14.12.2022 / As part of the IMMEDIATE project, a team led by ECRC researcher Friedemann Paul is investigating inflammatory precursors of diseases – and how nutrition and the gut microbiome influence the immune system. The project is receiving more than €7 million in EU funding. … more
Glycotope with South Korean partner against breast cancer
13.12.2022 / News Innovation / 20.12.2022 Change in the Supervisory Board of Eckert & Ziegler AG Innovation / 19.12.2022 Changes in the Management Board of Eckert & Ziegler economic development / 13.12.2022 Glycotope with South Korean partner against breast cancer Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer … more
The genes of the sixth sense
08.12.2022 / To perform coordinated movements, we rely on special sensory neurons in our muscles and joints. Without them, the brain wouldn’t know what the rest of our body was doing. A team led by Niccolò Zampieri has studied their molecular markers to better understand how they work and describes the results in “Nature Communications”. … more
Max Delbrück Center celebrates 30th anniversary
08.12.2022 / On December 7, the Max Delbrück Center in Berlin celebrated its 30th birthday with the inauguration of Maike Sander as the new Scientific Director. The diabetes researcher brings together scientific excellence, innovation, and medical applications. … more
OMEICOS Therapeutics Announces Expansion of OMT-28 Clinical Development Program into Primary Mitochondrial Diseases
08.12.2022 / OMT-28’s established safety profile, biomarker data, and funding secured from existing investors enable swift transition into a Phase II clinical study … more
From California to Berlin: Maike Sander
03.12.2022 / On November 1, 2022, Professor Maike Sander took over as Scientific Director of the Max Delbrück Center. The diabetes researcher succeeds Professor Thomas Sommer, who had directed the Center on an interim basis since 2019. … more
Through the eyes of Jeanne Mammen
28.11.2022 / Seeing the world through the eyes of Jeanne Mammen – this was the theme of a celebratory evening at Campus Buch to mark the 132nd birthday of the artist and friend of Max Delbrück. The reading officially opened the project CampusArt – Science and Art on the Campus. … more
What octopus and human brains have in common
26.11.2022 / Cephalopods like octopuses, squids and cuttlefish are highly intelligent animals with complex nervous systems. In “Science Advances”, a team led by Nikolaus Rajewsky of the Max Delbrück Center has now shown that their evolution is linked to a dramatic expansion of their microRNA repertoire. … more
Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR
25.11.2022 / PENTIXAPHARM GmbH, a 100% subsidiary of Eckert & Ziegler AG (ISIN DE0005659700, SDAX), received green light from the European Medicines Agency (EMA) to conduct a phase III registration study in patients suffering from various forms of Non-Hodgkin-Lymphomas. Following several rounds of scientific advice, the EMA Committee for Medicinal Products for Human Use (CHMP) endorsed a study design presented by PENTIXAPHARM’s management, which envisions treating up to 500 lymphoma patients with the Gallium-68 based radiotracer PENTIXAFOR in about 30 participating European clinics. In its endorsement the CHMP adopted the advice given by the EMA Scientific Advice Working Party, a multidisciplinary group, which comprises delegates from several national European Health Agencies, members of the Committee for Orphan Medicinal Products, the Paediatric Committee, the Committee for Advanced Therapies, and the Pharmacovigilance Risk Assessment Committee. The first treatments with PENTIXAFOR are expected to start in the first half of 2023, subject to approval by national health authorities. … more
ERC Starting Grants for Berlin scientists
22.11.2022 / They have their sights set on serious diseases: Gabriele G. Schiattarella analyzes mechanisms of heart failure, Simon Haas wants to improve immunotherapies for leukemia and Michael Sigal would like to prevent gastrointestinal diseases. Now, the ERC is awarding the researchers with a Starting Grant. … more
Cancer researcher Ulrike Stein receives high honor
16.11.2022 / Ulrike Stein is searching for molecules that play a key role in metastasis, aiming to use them as therapeutic targets for solid tumors and to improve cancer prognosis. The Metastasis Research Society has recognized her work with this year’s Women in Science Achievement Award. … more
Highly cited – and influential
15.11.2022 / Sofia Forslund, Friedemann Paul and Nikolaus Rajewsky are among the Highly Cited Researchers 2022. Each year, the company Clarivate lists researchers who have demonstrated significant influence in their field. In addition, Research.com has ranked Klaus Rajewsky as one of the world’s best scientists. … more
Events
all events
30.08.2023, 09:00-
02.09.2023, 18:30
From Target to Market - The GLA Biotech & Pharma Summer School
12.06.2023, 09:00-
13.06.2023, 17:00
realtime PCR und digital PCR Kurs
07.09.2023, 09:00-
08.09.2023, 17:00
Auswertung und Analyse von Proteinen mit Western Blot